Triveni to take ex­per­i­men­tal eczema drug to the clin­ic, backed by new $115M fi­nanc­ing round

On Wednes­day, Triveni Bio be­came the lat­est im­munol­o­gy and in­flam­ma­tion start­up this year to an­nounce a $100 mil­lion-plus fi­nanc­ing round.

Mon­ey has come thick and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER